

IL-8RB (E-2): sc-7304

BACKGROUND

IL-8 has been shown to function as a potent neutrophil chemostatic and activating peptide and is an important mediator of inflammatory diseases. Two distinct human IL-8 receptors, designated IL-8RA and IL-8RB, have been characterized. Both are expressed at a high level on neutrophils, and to a lesser extent on monocytes and myeloid cell lines. In addition, the IL-8RA subunit is expressed in T cells such as the Jurkat cell line. Both IL-8Rs are members of the seven transmembrane domain rhodopsin superfamily of receptors and as such, couple G proteins for signal transduction. The two receptors share 77% amino acid identity. IL-8RA exhibits high affinity binding for IL-8 and low affinity MGSA binding, whereas IL-8RB has high affinity binding for both IL-8 and MGSA.

CHROMOSOMAL LOCATION

Genetic locus: IL8RB (human) mapping to 2q35.

SOURCE

IL-8RB (E-2) is a mouse monoclonal antibody raised against amino acids 1-19 mapping at the N-terminus of IL-8RB of human origin.

PRODUCT

Each vial contains 200 µg IgG_{2a} lambda light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

IL-8RB (E-2) is available conjugated to agarose (sc-7304 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-7304 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-7304 PE), fluorescein (sc-7304 FITC), Alexa Fluor® 488 (sc-7304 AF488), Alexa Fluor® 546 (sc-7304 AF546), Alexa Fluor® 594 (sc-7304 AF594) or Alexa Fluor® 647 (sc-7304 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-7304 AF680) or Alexa Fluor® 790 (sc-7304 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

APPLICATIONS

IL-8RB (E-2) is recommended for detection of IL-8RB of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10⁶ cells).

Suitable for use as control antibody for IL-8RB siRNA (h): sc-40028, IL-8RB shRNA Plasmid (h): sc-40028-SH and IL-8RB shRNA (h) Lentiviral Particles: sc-40028-V.

Molecular Weight of IL-8RB: 45 kDa.

Positive Controls: IL-8RB (h): 293T Lysate: sc-115378 or human PBL whole cell lysate.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



IL-8RB (E-2): sc-7304. Western blot analysis of IL-8RB expression in non-transfected: sc-117752 (A) and human IL-8RB transfected: sc-176067 (B) 293T whole cell lysates.



IL-8RB (E-2): sc-7304. Immunoperoxidase staining of formalin fixed, paraffin-embedded human pancreas tissue showing membrane and cytoplasmic staining of glandular cells (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human esophagus tissue showing membrane staining of squamous epithelial cells. Kindly provided by The Swedish Human Protein Atlas (HPA) program (B).

SELECT PRODUCT CITATIONS

1. Fan, G.H., et al. 2001. Phosphorylation-independent association of CXCR2 with the protein phosphatase 2A core enzyme. *J. Biol. Chem.* 276: 16960-16968.
2. Uddin, M.M., et al. 2018. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy. *PLoS ONE* 13: e0201858.
3. Santos, T.D., et al. 2019. Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer. *Pathologica* 111: 62-66.
4. Boissière-Michot, F., et al. 2020. Prognostic value of CXCR2 in breast cancer. *Cancers* 12: 2076.
5. Boissière-Michot, F., et al. 2021. CXCR2 levels correlate with immune infiltration and a better prognosis of triple-negative breast cancers. *Cancers* 13: 2328.
6. Ghallab, A.M., et al. 2022. CXCR2 small-molecule antagonist combats chemoresistance and enhances immunotherapy in triple-negative breast cancer. *Front. Pharmacol.* 13: 862125.
7. Zhang, Z.Y., et al. 2023. Promotion of axon regeneration and protection on injured retinal ganglion cells by rCXCL2. *Inflamm. Regen.* 43: 31.
8. Hamshaw, I., et al. 2024. The role of PKC and PKD in CXCL12 and CXCL13 directed malignant melanoma and acute monocytic leukemic cancer cell migration. *Cell. Signal.* 113: 110966.
9. Kurniyati, K., et al. 2025. A bipartite bacterial virulence factor targets the complement system and neutrophil activation. *EMBO J.* 44: 1154-1184.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA